OmniAb
OmniAb's revenue fell 29.3% to $19 million in fiscal 2025. Its operating margin was −369.5%, down from −282.3% a year earlier. Free cash flow was −$37 million. The diluted share count rose 11.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What OmniAb does
OmniAb licenses antibody discovery technology to drug and biotech companies and to universities. Its platform uses genetically modified animals, including rats, chickens and mice, that make antibodies with human sequences, and it screens those antibodies one cell at a time to find candidates for its partners' drugs. It also offers computer tools and capabilities for ion channels and transporters, a hard class of drug targets.
It earns money under license agreements that generally include upfront or annual access fees, payments for research services, milestone payments and royalties on its partners' product sales. Academic partners typically share revenue instead. OmniAb says it expects milestones and services to drive revenue in the near term and royalties in the longer term, but says the timing of any drug approval is uncertain. It does not control how partners develop or sell the drugs.
At the end of 2025 it had 107 active partners with 407 active programs, including three approved products made by its partners.
Its biggest risks, as it describes them
- Biotech drugs from its partners' programs may never reach the market, so milestone and royalty payments may not come.
- Dependence on a limited number of partners for revenue, and on partners to report milestones and pay on time.
- Its lack of control over its partners' clinical trials, regulatory plans and sales efforts.
- Competition in antibody discovery technology, and fast technology change.
- Reliance on animal colonies, some hosted by third parties, that could suffer disease or public controversy.
Income statement
OmniAb lost money in fiscal 2025: a net loss of $65 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 0 | 88 | 87 | 59 | 54 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −5,087.0x | — | — | — | — |
| Current ratio | 1.1x | 4.8x | 4.1x | 4.5x | 4.0x |
| Quick ratio | 1.1x | 4.8x | 4.1x | 4.5x | 4.0x |
Cash flow
Projections
Project OmniAb's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of OmniAb reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −40.1% | −180.2% | −227.6% |
| Altman Z'' | 5.12 | 6.48 | 6.00 |
| Accruals ratio | −13.3% | −6.4% | −9.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put OmniAb side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| OmniAb | FY25 | −29.3% | −369.5% | −198.3% | — | — | — | |
| Personalis | FY25 | −17.7% | −126.4% | −114.1% | — | — | — | Compare |
| PacBio | FY25 | 3.9% | −346.1% | −71.2% | −77.1% | — | 3 | Compare |
| Ginkgo Bioworks | FY25 | −25.1% | −185.3% | −105.0% | — | — | — | Compare |
| Cryoport | FY25 | 12.4% | −20.9% | −14.2% | −23.4% | — | 4 | Compare |
5 years of figures
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 35 | 59 | 34 | 26 | 19 |
| Revenue growth | — | 70.0% | −42.2% | −22.8% | −29.3% |
| Gross profit | — | — | — | — | — |
| Research and development | 39 | 48 | 56 | 55 | 48 |
| Operating income | −36 | −27 | −69 | −74 | −69 |
| Net income | −27 | −22 | −51 | −62 | −65 |
| Diluted EPS (US$) | −0.33 | −0.26 | −0.51 | −0.61 | −0.57 |
| Diluted shares (millions) | 83 | 85 | 100 | 102 | 114 |
| Cash flow | |||||
| Cash from operations | −6 | −4 | 2 | −40 | −36 |
| Capital expenditure | 4 | 17 | 2 | 2 | 1 |
| Free cash flow | −10 | −21 | 1 | −42 | −37 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 15 | 18 | 25 | 22 | 16 |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 0 | 88 | 87 | 59 | 54 |
| Debt incl. finance leases | — | — | — | — | — |
| Total assets | 304 | 421 | 375 | 326 | 301 |
| Total liabilities | 70 | 80 | 61 | 38 | 34 |
| Shareholders' equity | 234 | 341 | 315 | 288 | 267 |
| Margins and ratios | |||||
| Gross margin | — | — | — | — | — |
| Operating margin | −102.5% | −45.1% | −203.2% | −282.3% | −369.5% |
| Net margin | −77.8% | −37.8% | −148.2% | −235.1% | −347.0% |
| Free cash flow margin | −28.0% | −35.1% | 2.1% | −157.4% | −198.3% |
| Rule of 40 (growth + FCF margin) | — | 34.9% | −40.1% | −180.2% | −227.6% |
| Return on capital | — | — | — | — | — |
| Return on equity | — | −7.8% | −15.4% | −20.6% | −23.4% |
| Return on assets | — | −6.2% | −12.7% | −17.7% | −20.7% |
| Net debt to EBITDA | — | — | — | — | — |